1
|
Karamichalakis N, Kolovos V, Paraskevaidis I, Tsougos E. A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation. J Cardiovasc Dev Dis 2022; 9:jcdd9080236. [PMID: 35893226 PMCID: PMC9331782 DOI: 10.3390/jcdd9080236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2022] [Revised: 07/17/2022] [Accepted: 07/22/2022] [Indexed: 11/16/2022] Open
Abstract
Atrial arrhythmias are common in patients with diabetes mellitus (DM), and despite recent advances in pharmaceutical and invasive treatments, atrial fibrillation (AF) and atrial flutter (AFl) are still associated with substantial mortality and morbidity. Clinical trial data imply a protective effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on the occurrence of AF and AFl. This review summarizes the state of knowledge regarding DM-mediated mechanisms responsible for AF genesis and recurrence but also discusses the recent data from experimental studies, published trials and metanalyses.
Collapse
|
2
|
Choulitoudi V, Oikonomaki T, Bletsa A, Ampelakiotou K, Panagakou S, Koutroumpas G, Palla V, Panagopoulou P, Adamidis K, Kogkaki E, Dardioti V, Kousouls V, Kolovos V, Pomoni S, Kontou E, Tsirogianni A, Christodoulidou C. MO906: Antibody Response to COVID-19 Vaccination in Patients Under Dialysis. Nephrol Dial Transplant 2022. [PMCID: PMC9383934 DOI: 10.1093/ndt/gfac084.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND AND AIMS Patients (pts) with end-stage kidney disease (ESRD) may be more vulnerable to infections and may have a suboptimal response to vaccination. Dialysis patient (pt) began to be vaccinated against COVID-19 in February 2021. However, there were many doubts about whether immunization would be effective for them, as these pts have an impaired immune system, and it seems that this population responds poorly to vaccinations. Serum neutralizing antibodies (AbN) rapidly appear after the SARS-CoV-2 infection and the vaccination and are maintained for several months. The emergence of SARS-CoV-2 variants has raised concerns about the breadth of the neutralizing antibody responses. METHOD Serum samples were obtained from 181 patients receiving dialysis. Levels of circulating SARS-CoV-2 anti-spike IgG(S) and anti-nucleocapsid IgG (N) antibodies were quantified using the Abbott Diagnostics SARS-CoV-2 IgG chemiluminescent microparticle immunoassay (Abbott Diagnostics, Abbott Park, IL, USA) on an Abbott Diagnostics Architect i2000 SR and an Alinity analyzer, according to the manufacturer's instructions. Serum neutralizing antibodies (AbN) by commercially available assays (cPass SARS-CoV-2 Neutralization Antibody Detection Kit), at the first and the third months after the vaccination, were identified. RESULTS The IgG-spike Abs had a statistically significant decrease at 3 months after the vaccination in relation to the measurements 1 month after that. AbN had a statistically significant decline at 3 months after the vaccination in relation to the measurements 1 month after. Pts with cardiovascular disease (CD) had significantly lower levels of antibodies than those who did not have CD. Additionally, CD was an aggravating factor in combination with the other comorbidities for the development of antibodies. Pts with a history of malignancy had significantly lower levels of antibodies in relation to those who did not. Those under therapy with antihistamines in the 1st month after the vaccination presented a statistically lower level of the AbNs, but this difference did not exist in the measurements 3 months after vaccination. There was a correlation between the AbNs and the age, also between the time these patients underwent dialysis. Those who had COVID-19 infection presented higher levels of the antibodies AbN/IgG-spiked Ab at 3 months. CONCLUSION It is presented that the IgG-spike Abs and the AbN had a statistically significant decrease at 3 months after the vaccination, which shows the importance of completing vaccination with the third dose after 3 months. Also, it is presented that CD is a risk factor for lower levels of Abs. Randomized clinical trials for COVID-19 vaccines included a few patients with kidney disease; therefore, the vaccine immunogenicity is uncertain in this population.
Collapse
Affiliation(s)
| | | | - Anastasia Bletsa
- Immunology- Histocompatibility, Evaggelismos General Hospital, Athens, Greece
| | - Kleio Ampelakiotou
- Immunology- Histocompatibility, Evaggelismos General Hospital, Athens, Greece
| | | | | | | | | | | | | | | | | | | | - Stella Pomoni
- Immunology- Histocompatibility, Evaggelismos General Hospital, Athens, Greece
| | - Elisavet Kontou
- Immunology- Histocompatibility, Evaggelismos General Hospital, Athens, Greece
| | | | | |
Collapse
|
3
|
Ikonomidis A, Venetis C, Georgantzis D, Giaslakiotis V, Kolovos V, Efstathiou K, Moschou M, Κoutsiaris Ε, Panopoulou M. Prevalence of Chlamydia trachomatis, Ureaplasma spp., Mycoplasma genitalium and Mycoplasma hominis among outpatients in central Greece: absence of tetracycline resistance gene tet(M) over a 4-year period study. New Microbes New Infect 2015; 9:8-10. [PMID: 26862428 PMCID: PMC4706606 DOI: 10.1016/j.nmni.2015.11.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Revised: 11/04/2015] [Accepted: 11/04/2015] [Indexed: 10/30/2022] Open
Abstract
A total of 301 men and women attending local urologists and gynaecologists in the state of Thessaly, central Greece, were tested for Chlamydia trachomatis, Ureaplasma spp., Mycoplasma genitalium and Mycoplasma hominis DNA. Investigation of the tet(M) gene, which confers tetracycline resistance in these genera, was also performed. Low incidence of C. trachomatis and Mycoplasma spp. as well as high prevalence of Ureaplasma spp., especially among women, were found. The tet(M) gene was absent in all cases, notably in a region where doxycycline administration remains the first therapeutic option unless special medical conditions direct otherwise.
Collapse
Affiliation(s)
- A Ikonomidis
- Biogonidiaki, Center of Infertility Investigation and Genetic Research, Volos, Greece; Democritus University of Thrace, Department of Microbiology, Alexandroupolis, Greece
| | - C Venetis
- Biogonidiaki, Center of Infertility Investigation and Genetic Research, Volos, Greece
| | - D Georgantzis
- Biogonidiaki, Center of Infertility Investigation and Genetic Research, Volos, Greece
| | - V Giaslakiotis
- Biogonidiaki, Center of Infertility Investigation and Genetic Research, Volos, Greece
| | - V Kolovos
- Biogonidiaki, Center of Infertility Investigation and Genetic Research, Volos, Greece
| | - K Efstathiou
- Biogonidiaki, Center of Infertility Investigation and Genetic Research, Volos, Greece
| | - M Moschou
- Biogonidiaki, Center of Infertility Investigation and Genetic Research, Volos, Greece
| | - Ε Κoutsiaris
- Biogonidiaki, Center of Infertility Investigation and Genetic Research, Volos, Greece
| | - M Panopoulou
- Democritus University of Thrace, Department of Microbiology, Alexandroupolis, Greece
| |
Collapse
|
4
|
Ziakka S, Zagorianakos A, Koutsovasili A, Kaperonis N, Poulikakos D, Sgantzos A, Kolovos V, Ntatsis G, Papagalanis N. Efficacy of hemopoietic-stimulating factors in patients undergoing chronic hemodialysis. Ren Fail 2011; 33:923-8. [PMID: 22013927 DOI: 10.3109/0886022x.2011.615963] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Anemia has been linked to increased mortality and morbidity in renal hemodialysis patients. Other risk factors that contribute to an adverse outcome include the variability of hemoglobin (Hb) levels and the decreased response to erythropoiesis-stimulating factors (ESFs). In this study we evaluated the effectiveness of four different ESFs (epoetin-A, epoetin-B, darbepoetin, and CERA), assessed the variability of Hb levels, and compared ESF dosages which contributed to the achievement of Hb levels in each individual patient with renal failure undergoing chronic hemodialysis maintenance. In conclusion, the four ESFs administered are equally effective in the treatment of anemia in renal hemodialysis patients and they do not influence in a different manner the variability of Hb. The administration of darbepoetin-A and CERA might possibly cause more patients to overshoot the target level of Hb.
Collapse
Affiliation(s)
- Stavroula Ziakka
- Nephrology Clinic, Hellenic Red Cross Hospital Korgialeneio-Benakeio, Athens, Greece
| | | | | | | | | | | | | | | | | |
Collapse
|